Plasmodium Falciparum Infection Clinical Trial
Official title:
Host and Parasites Factors Contributing to Risk of Plasmodium Re-infection and Morbidity in Elementary School Children in Maprik, East Sepik Province
This study specifically seeks to quantify the contribution of relapes to the burden of P.
vivax infections and disease by determining on the effect of radical pre-erythrocytic and
erythrocytic clearance on subsequent rates of Plasmodium spp. infection and disease in
children aged 5-10 years in a treatment to re-infection study design. In order the clear
liver-stage/blood-stages G6PD-normal children were randomised to receive Chloroquine (3
days, standard dose) and Coartem (3 days, standard dose) plus either i) primaquine (20 days,
0.5mg/kg) or ii) placebo (20days). These drugs were administered over a period of 4 weeks.
In addition to this epidemiological data, the study will assess the natural acquisition of
cellular and humoral immune responses to P. falciparum and P. vivax, thus assisting in the
determination of correlates of clinical immunity to P. falciparum and P. vivax in PNG
children aged 5-10 years.
These data will not only be essential for development of future vaccines against P. vivax
and P falciparum but provide invaluable insight into the contribution of long-lasting
liver-stages to the force of infection with P. vivax that will contribute towards designing
more rational approaches to the treatment of P. vivax both in the context of case management
and future attempts at elimination.
n/a
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Basic Science
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05400655 -
Anti-malaria MAb in Kenyan Children
|
Phase 2 | |
| Completed |
NCT02773979 -
PfSPZ Challenge in Healthy Malaria-Naïve Adults in the United States
|
Phase 1 | |
| Completed |
NCT03660839 -
Study to Investigate the Clinical and Parasiticidal Activity and Pharmacokinetics of Different Doses of Artefenomel and Ferroquine in Patients With Uncomplicated Plasmodium Falciparum Malaria
|
Phase 2 | |
| Terminated |
NCT00988507 -
Dose Ranging Study of Ferroquine With Artesunate in African Adults and Children With Uncomplicated Plasmodium Falciparum Malaria
|
Phase 2 | |
| Recruiting |
NCT05750459 -
Pharmacokinetic Study of IV Artesunate to Treat Children With Severe Malaria
|
Phase 4 | |
| Completed |
NCT02020330 -
Optimising Operational Use of Artemether-lumefantrine Comparing 3 Day Versus 5 Day
|
Phase 3 | |
| Completed |
NCT05816330 -
L9LS MAb in Malian Adults
|
Phase 2 | |
| Completed |
NCT02353494 -
Efficacy and Safety of Dihydroartemisinin-piperaquine (DHP) for the Treatment of Uncomplicated Malaria
|
N/A | |
| Completed |
NCT00744133 -
Malaria Challenge With NF54 Strain
|
Phase 1 | |
| Active, not recruiting |
NCT05304611 -
Anti-malaria MAb in Malian Children
|
Phase 2 | |
| Completed |
NCT03014258 -
A Systems Biology Approach to Malaria Immunity
|
Phase 1 | |
| Completed |
NCT03168854 -
Trial to Evaluate the Safety, Immunogenicity and Protective Efficacy of Three or Five Administrations of GAP3KO Sporozoites
|
Phase 1 | |
| Terminated |
NCT02497612 -
To Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of a Single Dose Regimen of Ferroquine and Artefenomel in Adults and Children With Uncomplicated Plasmodium Falciparum Malaria
|
Phase 2 | |
| Completed |
NCT00371189 -
Adenovirus Vaccine for Malaria
|
Phase 1 | |
| Not yet recruiting |
NCT05025761 -
Reducing Malaria Transmission in Forest-going Mobile and Migrant Populations in Myanmar
|
N/A | |
| Completed |
NCT00379821 -
Chloroquine Alone or in Combination for Malaria in Children in Malawi
|
Phase 3 | |
| Completed |
NCT04329104 -
Safety and Efficacy of CIS43LS Anti-malaria mAb in Mali
|
Phase 2 | |
| Completed |
NCT03589794 -
rCSP/AP10-602 [GLA-LSQ] Vaccine Trial
|
Phase 1 | |
| Completed |
NCT02780154 -
PfSPZ Challenge in Non-immune Adults in Baltimore, USA
|
Phase 1 | |
| Completed |
NCT02663700 -
Safety and Immunogenicity of Sanaria's Irradiated Sporozoite Vaccine (PfSPZ Vaccine) in Malaria-Experienced Adults in Burkina Faso
|
Phase 1 |